Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
Eleonora Russo, Giuseppe Penno, Stefano Del Prato Department of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Disease, Azienda Ospedaliero Universitaria di Pisa, and University of Pisa, Pisa, Italy Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel classified ora...
Enregistré dans:
Auteurs principaux: | Russo E, Penno G, Del Prato S |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/48d2c4b76bb942349b9033e8f089a3d7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
par: Gallwitz B
Publié: (2013) -
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
par: Bo Ahrén
Publié: (2010) -
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
par: Kishimoto M
Publié: (2013) -
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
par: Ahren B
Publié: (2010) -
Alogliptin: a new addition to the class of DPP-4 inhibitors
par: Radha Andukuri, et autres
Publié: (2009)